ORKA
Oruka Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
+9/100
Last price
80.25
▼ 4.13 (4.89%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
84.01
Prev close
84.38
Day high
84.94
Day low
77.78
Volume
1.12M
Market cap
$5.31B
P/E (TTM)
—
52W range
20.25 – 115.52
Day trading desk
Gap from prior close
-0.44%
Prior close 84.38
VWAP
80.20
+0.06% from price
Relative volume
2.35×
Unusually busy
Session range
9.21%
77.78 – 84.94
Position in range
34%
Mid range
ATR (14D)
4.62
5.75% of price
Prior day high
85.23
PDH
Prior day low
81.83
PDL
Bid / ask spread
—
Quote not published
Session volume
2.09M
Avg 889.85K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-2.40%
-4.3%
1M
-13.33%
-14.5%
3M
-5.00%
-9.5%
6M
+32.31%
+14.1%
YTD
+164.53%
+150.3%
1Y
+305.15%
+288.7%
3Y
+232.42%
+150.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ORKA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+7.38K
Net buying
Buy transactions
20
3.96M shares
Sell transactions
28
3.95M shares
Net transactions
+48
Buys less sells
Sell : buy shares
1.0 : 1
Mixed
Insider-held shares
832.25K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 21, 26 | AGARWAL ARJUN Officer |
SELL | 533 | $51.03K | Direct |
| Sep 21, 26 | QUINLAN PAUL T General Counsel |
SELL | 10.00K | $936.42K | Direct |
| Sep 21, 26 | QUINLAN PAUL T General Counsel |
CONVERSION | 10.00K | $78.00K | Direct |
| Sep 15, 26 | GONCALVES JOANA Officer |
SELL | 7.95K | $734.14K | Direct |
| Sep 15, 26 | KLEIN LAWRENCE OTTO Chief Executive Officer |
SELL | 2.45K | $234.68K | Direct |
| Sep 15, 26 | AGARWAL ARJUN Officer |
SELL | 10.02K | $926.01K | Direct |
| Sep 15, 26 | SANDLER LAURA LEE Chief Operating Officer |
SELL | 906 | $86.71K | Direct |
| Sep 15, 26 | QUINLAN PAUL T General Counsel |
SELL | 1.04K | $99.44K | Direct |
| Sep 15, 26 | GONCALVES JOANA Officer |
CONVERSION | 7.00K | $51.24K | Direct |
| Sep 11, 26 | AGARWAL ARJUN Officer |
CONVERSION | 9.46K | $150.18K | Direct |
| Sep 1, 26 | KLEIN LAWRENCE OTTO Chief Executive Officer |
SELL | 75.00K | $6.89M | Direct |
| Sep 1, 26 | SANDLER LAURA LEE Chief Operating Officer |
SELL | 5.00K | $459.10K | Direct |
| Sep 1, 26 | KLEIN LAWRENCE OTTO Chief Executive Officer |
CONVERSION | 75.00K | $585.00K | Direct |
| Sep 1, 26 | SANDLER LAURA LEE Chief Operating Officer |
CONVERSION | 5.00K | $39.00K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AGARWAL ARJUN |
Officer | 14.22K | Sale |
DAMBKOWSKI CARL |
Director | 38.74K | Sale |
EDWARDS LARRY TODD |
Officer | 100.00K | Stock Award(Grant) |
FAIRMOUNT FUNDS MANAGEMENT LLC |
Beneficial Owner of more than 10% of a Class of Security | — | Sale |
GONCALVES JOANA |
Officer | 31.77K | Sale |
KLEIN LAWRENCE OTTO |
Chief Executive Officer | 923.13K | Sale |
QUINLAN PAUL T |
General Counsel | 30.00K | Sale |
SANDLER LAURA LEE |
Chief Operating Officer | 235.48K | Sale |
VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Fundamentals
Market cap$5.31B
Enterprise value$4.44B
Revenue (TTM)—
Gross profit—
EBITDA$-154.94M
Net income$-109.69M
EPS (TTM)$-2.04
Free cash flow$-65.03M
Total cash$873.56M
Total debt$2.55M
Book value / share$18.20
Shares outstanding66.21M
Float56.89M
Short % of float16.76%
Dividend yield0.00%
Beta (5Y)-0.11
Valuation & profitability ratios
Trailing P/E—
Forward P/E-28.01
PEG ratio—
Price / sales—
Price / book4.41
EV / revenue—
EV / EBITDA-28.66
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-18.23%
Return on assets-12.95%
Debt / equity0.23
Current ratio38.51
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | YoY |
|---|---|---|
| Total revenue | $0 | |
| Operating revenue | $0 | |
| Research & development | $100.64M | |
| Selling, general & admin | $21.41M | |
| Total operating expense | $122.05M | |
| Operating income | -$122.05M | |
| Net interest income | $16.63M | |
| Pre-tax income | -$105.43M | |
| Net income | -$105.43M | |
| Net income to common | -$105.43M | |
| Basic EPS | -1.85 | |
| Diluted EPS | -1.85 | |
| EBIT | -$105.43M | |
| EBITDA | -$105.35M | |
| Basic shares | 45.61M | |
| Diluted shares | 45.61M |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $46.94M | $61.58M | -23.8% |
| Cash & short-term investments | $337.04M | $375.65M | -10.3% |
| Total current assets | $343.86M | $376.87M | -8.8% |
| Property, plant & equipment | $2.12M | $1.04M | +104.0% |
| Total assets | $488.62M | $396.02M | +23.4% |
| Total current liabilities | $15.37M | $13.04M | +17.9% |
| Total debt | $1.93M | $968.00K | +99.6% |
| Total liabilities | $19.62M | $16.73M | +17.3% |
| Retained earnings | -$189.16M | -$83.72M | -125.9% |
| Shareholder equity | $469.00M | $379.29M | +23.7% |
| Working capital | $328.48M | $363.83M | -9.7% |
| Net tangible assets | $469.00M | $379.29M | +23.7% |
| Shares issued | 48.72M | 37.44M | +30.1% |
| Line item | 2025 | YoY |
|---|---|---|
| Net income | -$105.43M | |
| Depreciation & amortisation | $83.00K | |
| Stock-based compensation | $24.24M | |
| Change in working capital | -$2.56M | |
| Operating cash flow | -$88.21M | |
| Capital expenditure | -$209.00K | |
| Investing cash flow | -$96.75M | |
| Financing cash flow | $170.31M | |
| Free cash flow | -$88.42M | |
| End cash position | $46.94M |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $43.26M | $29.14M | $27.64M | $28.99M | $24.09M | — | +48.4% |
| Selling, general & admin | $6.85M | $7.29M | $6.79M | $5.12M | $4.34M | — | -6.0% |
| Total operating expense | $50.11M | $36.43M | $34.43M | $34.10M | $28.43M | — | +37.5% |
| Operating income | -$50.11M | -$36.43M | -$34.43M | -$34.10M | -$28.43M | — | -37.5% |
| Net interest income | $8.90M | $4.61M | $4.85M | $3.83M | $3.86M | — | +93.2% |
| Pre-tax income | -$41.21M | -$31.82M | -$29.58M | -$30.28M | -$24.57M | — | -29.5% |
| Net income | -$41.21M | -$31.82M | -$29.58M | -$30.28M | -$24.57M | — | -29.5% |
| Net income to common | -$41.21M | -$31.82M | -$29.58M | -$30.28M | -$24.57M | — | -29.5% |
| Basic EPS | -0.55 | -0.48 | — | -0.55 | -0.46 | -0.40 | -14.6% |
| Diluted EPS | -0.55 | -0.48 | — | -0.55 | -0.46 | -0.40 | -14.6% |
| EBIT | -$50.11M | -$36.43M | -$29.58M | -$30.28M | -$28.43M | — | -37.5% |
| EBITDA | -$50.06M | -$36.39M | -$29.55M | -$30.26M | -$28.41M | — | -37.6% |
| Basic shares | 63.01M | 55.31M | — | 44.20M | 42.23M | 41.82M | +13.9% |
| Diluted shares | 63.01M | 55.31M | — | 44.20M | 42.23M | 41.82M | +13.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $268.47M | $49.52M | $46.94M | $91.25M | $65.40M | +442.1% |
| Cash & short-term investments | $873.56M | $388.83M | $337.04M | $349.15M | $328.41M | +124.7% |
| Total current assets | $884.56M | $395.25M | $343.86M | $355.16M | $332.01M | +123.8% |
| Property, plant & equipment | $2.69M | $2.00M | $2.12M | $2.22M | $2.25M | +34.2% |
| Total assets | $1.14B | $504.48M | $488.62M | $509.25M | $357.42M | +125.9% |
| Total current liabilities | $22.97M | $16.63M | $15.37M | $20.97M | $12.11M | +38.1% |
| Total debt | $2.55M | $1.81M | $1.93M | $1.91M | $2.33M | +40.9% |
| Total liabilities | $27.78M | $20.69M | $19.62M | $22.46M | $13.78M | +34.2% |
| Retained earnings | -$262.18M | -$220.98M | -$189.16M | -$159.57M | -$129.30M | -18.6% |
| Shareholder equity | $1.11B | $483.79M | $469.00M | $486.79M | $343.64M | +129.8% |
| Working capital | $861.59M | $378.62M | $328.48M | $334.20M | $319.90M | +127.6% |
| Net tangible assets | $1.11B | $483.79M | $469.00M | $486.79M | $343.64M | +129.8% |
| Shares issued | 61.07M | 50.17M | 48.72M | 48.38M | 37.45M | +21.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$41.21M | -$31.82M | -$29.58M | -$30.28M | -$24.57M | — | -29.5% |
| Depreciation & amortisation | $43.00K | $43.00K | $28.00K | $20.00K | $19.00K | — | 0.0% |
| Stock-based compensation | $7.28M | $6.97M | $4.12M | $10.16M | $5.08M | — | +4.5% |
| Change in working capital | $1.54M | $1.53M | $3.37M | -$602.00K | -$2.29M | — | +0.4% |
| Operating cash flow | -$33.15M | -$23.58M | -$22.59M | -$21.60M | -$23.14M | — | -40.6% |
| Capital expenditure | — | -$73.00K | -$63.00K | -$99.00K | -$34.00K | -$13.00K | — |
| Investing cash flow | -$410.95M | -$14.44M | -$22.02M | -$122.45M | $4.86M | — | -2,746.5% |
| Financing cash flow | $663.04M | $40.60M | $298.00K | $169.91M | $109.00K | — | +1,533.1% |
| Free cash flow | -$33.15M | -$23.65M | -$22.66M | -$21.70M | -$23.18M | — | -40.1% |
| End cash position | $268.47M | $49.52M | $46.94M | $91.25M | $65.40M | — | +442.1% |
Options analytics
Put / call volume
0.18
Call-heavy session
Put / call open interest
1.07
Positioning, not flow
Max pain
95.00
+18.5% from spot
ATM implied vol
69.2%
Nearest strike to spot
Skew (10% OTM)
+27.1%
Puts bid over calls
Call volume
110
Contracts, this expiry
Put volume
20
Contracts, this expiry
Heaviest call OI
85.00
92 contracts
Heaviest put OI
95.00
103 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.50 | -0.55 | -10.0% |
| Mar 2026 | -0.54 | -0.48 | +10.6% |
| Dec 2025 | -0.62 | -0.45 | +26.9% |
| Sep 2025 | -0.52 | -0.55 | -5.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.62 | 9 | $0 | 0.0% |
| Next quarter | -0.66 | 9 | $0 | 0.0% |
| Current year | -2.37 | 9 | $0 | 0.0% |
| Next year | -2.86 | 9 | $0 | 0.0% |
Analyst targets & ownership
Mean target$155.00
High target$200.00
Low target$117.00
Implied upside93.15%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy2 / 11
Hold0
Sell / Strong sell0 / 0
Held by insiders1.26%
Held by institutions116.60%
Institutions holding345
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
84.20
-4.69% from price
SMA 20
88.99
-9.90% from price
SMA 50
95.41
-15.96% from price
SMA 100
85.37
-6.00% from price
SMA 200
64.46
+24.39% from price
EMA 12
85.55
-6.20% from price
EMA 26
89.18
-10.01% from price
EMA 50
90.21
-11.04% from price
RSI (14)
32.3
Neutral
MACD (12,26,9)
-3.63
Hist -0.67
ATR (14)
4.62
5.76% of price
Realised vol 30D
40.9%
Annualised
Bollinger upper
99.50
20, 2σ
Bollinger lower
78.48
20, 2σ
50 / 200 cross
Golden
95.41 vs 64.46
Trend bias
Above 200
+24.39%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.37
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
40.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-29.1%
Peak to trough
Max drawdown 5Y
-86.4%
Peak to trough
ATR 14
4.62
5.76% of price
Beta (reported)
-0.11
5Y monthly, from filing
Short interest
Shares short
7.62M
Prior 8.30M
Change vs prior
-8.2%
Shorts covering
% of float
16.76%
Elevated
% of shares out
11.51%
Against total outstanding
Days to cover
9.9
Crowded exit
Float
56.89M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 24, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 24, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 11, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Aug 11, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Aug 11, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 13, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jul 1, 26 | UBS | MAINTAINED | Buy | Buy |
| Jun 23, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 18, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 14, 26 | BTIG | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay dateAug 28, 2024
Last split1:12
Split dateSep 3, 2024
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-24
Offering Registrations
S-3 · 2026-08-21
Corporate Changes & Voting Matters
8-K · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-06-04
Corporate Changes & Voting Matters
8-K · 2026-06-01
Periodic Financial Reports
10-Q · 2026-05-13
Corporate Changes & Voting Matters
8-K · 2026-04-30
Corporate Changes & Voting Matters
8-K · 2026-04-27
Headlines
Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says
MT Newswires · 12d ago
ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data
Zacks · 13d ago
What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders
Simply Wall St. · 13d ago
The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data
Investor's Business Daily · 13d ago
Update: Oruka Shares Fall Despite Deepening Week 28 Responses for ORKA-001
MT Newswires · 13d ago
Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy
Benzinga · 14d ago
Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data
InvestorsHub · 14d ago
Oruka Therapeutics Reports Deepening Responses for ORKA-001 Through Week 28
MT Newswires · 14d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.